This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
In this episode titled: CRISPR/Cas: exploring its impact on gene editing, we explore the latest technological advancements in the field and more.
This conversation features Dr Pietro De Angeli, Scientist at Tubingen University Hospital, and Dr Maarten Guerts, Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology.
Key learning points:
What comparative safety profiles exist between utilising plasmid DNA, mRNA, and ribonucleoproteins (RNPs) as delivery systems for CRISPR/Cas components in gene editing therapies?
In what ways might the use of different ex-vivo applications affect the scalability and feasibility of large-scale gene editing treatments?
How might the convergence of CRISPR/Cas technology with Artificial Intelligence/Machine Learning improve precision medicine?
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
